Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide PI Susceptibility
Background: Protease inhibitor (PI)- based regimens are the mainstay of antiretroviral therapy for HIV-2. However, HIV-2 exhibits some degree of intrinsic resistance to the majority of FDA-approved PI, only retaining clinically-useful susceptibility to lopinavir, darunavir, and saquinavir. The mechanisms for this resistance remain largely unknown; although HIV-1 and HIV-2 proteases share only 40-50% sequence identity,…